Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis-Reference-Cited by-同舟云学术

Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis

Published:2012-03-14 Issue:4 Volume:33 Page:1231-1236
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Kalles Vasileios,Zografos George C.,Provatopoulou Xeni,Kalogera Eleni,Liakou Paraskevi,Georgiou Georgia,Sagkriotis Alexandros,Nonni Aphroditi,Gounaris Antonia

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-012-0371-x.pdf

Reference45 articles.

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.

2. Levin ER. Endothelins. N Engl J Med. 1995;333:356–63.

3. Williams Jr DL, Jones KL, Colton CD, Nutt RF. Identification of high affinity endothelin-1 receptor subtypes in human tissues. Biochem Biophys Res Commun. 1991;180:475–80.

4. Hoyer D, Waeber C, Palacios JM. [125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans. J Cardiovasc Pharmacol. 1989;13 Suppl 5:S162–5.

5. Masaki T. Tissue specificity of the endothelin-induced responses. J Cardiovasc Pharmacol. 1991;17 Suppl 7:S1–4.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic underpinnings of cancer-related fatigue;American Journal of Physiology-Endocrinology and Metabolism;2024-03-01

2. Endothelin-1 and Its Role in Cancer and Potential Therapeutic Opportunities;Biomedicines;2024-02-23

3. Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy;Russian Open Medical Journal;2020-09-30

4. Differences in Endothelin B Receptor Isoforms Expression and Function in Breast Cancer Cells;Journal of Cancer;2020

5. Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia;Oncotarget;2017-09-27